从实验室到临床:大麻二酚在神经胶质瘤中的应用。
From bench to bedside: the application of cannabidiol in glioma.
发表日期:2024 Jul 11
作者:
Shiying Feng, Yuanming Pan, Pu Lu, Na Li, Wei Zhu, Zhiqiang Hao
来源:
Journal of Translational Medicine
摘要:
胶质瘤是中枢神经系统最常见的恶性肿瘤,给患者带来巨大的健康负担。由于胶质瘤的内在特点以及治疗方式缺乏突破,大多数患者的预后仍然较差。这给全世界带来了沉重的心理和经济负担。近年来,大麻二酚(CBD)因其抗肿瘤、抗炎和神经保护等特性而受到广泛关注和研究。该综述全面总结了 CBD 在胶质瘤治疗中的临床前和临床研究,以及 CBD 纳米药物制剂的现状,并讨论了 CBD 在未来胶质瘤治疗中的潜力和挑战。© 2024。作者(s)。
Glioma is the most common malignant tumor in central nervous system, with significant health burdens to patients. Due to the intrinsic characteristics of glioma and the lack of breakthroughs in treatment modalities, the prognosis for most patients remains poor. This results in a heavy psychological and financial load worldwide. In recent years, cannabidiol (CBD) has garnered widespread attention and research due to its anti-tumoral, anti-inflammatory, and neuroprotective properties. This review comprehensively summarizes the preclinical and clinical research on the use of CBD in glioma therapy, as well as the current status of nanomedicine formulations of CBD, and discusses the potential and challenges of CBD in glioma therapy in the future.© 2024. The Author(s).